AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study

AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP).

  • The study failed to meet its primary endpoint of improvement on disease severity index from baseline at week 16, compared to placebo.
  • PPP is an autoimmune disorder characterized by blister-like sores on the palms of hands and feet' soles.
  • Improvement in disease severity index at week 16 was 6.1 for imsidolimab-treated patients, compared to 6.3 in the placebo group.
  • The mean change in disease severity from baseline was 5.78 or 38% improvement in the Imsidolimab arm, versus 6.78 or 33% improvement on the placebo.
  • Nine patients achieved 50% improvement, and four patients achieved 75% improvement in the imsidolimab arm at week 16, compared to 12 and 3 responders in the placebo arm, respectively.
  • Five imsidolimab-treated patients achieved almost clear skin at week 16 relative to 3 on placebo.
  • Further development in PPP is not currently anticipated, but the company will continue developing imsidolimab in five other immuno-dermatological indications.
  • Phase 3 study in generalized pustular psoriasis will start during mid-2021.
  • Imsidolimab was generally well-tolerated with a similar frequency of adverse events between treatment groups, and no severe or serious adverse events were observed in the imsidolimab arm. 
  • Price Action: ANAB shares trading has been halted, set to resume at 8:30 am EST.
Loading...
Loading...
ANAB Logo
ANABAnaptysBio Inc
$23.60-1.17%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
88.47
Growth
Not Available
Quality
Not Available
Value
19.77
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...